This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yesilova, Z. Articles by Ozdemír, I. C. Search for Related Content PubMed PubMed Citation Articles by Yesilova, Z. Articles by Ozdemír, I. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB TESTOSTERONE

The Effects of Gonadotropin Treatment on the Immunological Features of Male Patients with Idiopathic Hypogonadotropic Hypogonadism

Departments of Endocrinology and Metabolism (M.O., I.C.O.), Internal Medicine (Z.Y., I.H.K.), Hydroclimatology (M.T.), and Immunology (A.P., A.S.), Gulhane School of Medicine, 06018 Etlik-Ankara, Turkey

Address all correspondence and requests for reprints to: Metin Ozata, M.D., Department of Endocrinology and Metabolism, Gulhane School of Medicine, 06018 Etlik-Ankara, Turkey. E-mail: mozata{at}obs.gata.edu.tr

There is a significant line of evidence for a role of androgens in the modulation of the immune system. However, little is known about immunological features of male patients with idiopathic hypogonadotropic hypogonadism (IHH) and the potential effects of gonadotropin treatment. Thus, the objective of this study was to evaluate the levels of selected soluble immune parameters [IgA, IgG, IgM, C3c, C4, interleukin-2 (IL-2), and IL-4], the CD4⁺/CD8⁺ ratio, and counts of total lymphocyte and some subpopulation of lymphocytes (CD3⁺, CD4⁺, CD8⁺, and CD19⁺ cells) before and after gonadotropin treatment in men with IHH. Twenty-nine IHH patients and 19 age-matched healthy controls were included in the study. The patients were treated with human menopausal gonadotropin/hCG for 6 months.

The pretreatment levels of serum Igs, C3c, IL-2, and IL-4 in the patients were significantly higher than those in the controls (P < 0.001 for all). After treatment, all Igs (P < 0.001), C3c (P < 0.01), and IL-2 and IL-4 levels (P < 0.005) were decreased significantly compared to pretreatment levels. Pretreatment lymphocyte counts (P < 0.05); the percentages of CD3⁺ cells (P < 0.001), CD4⁺ cells (P < 0.001), and CD19⁺ cells (P < 0.001); and the CD4⁺/CD8⁺ ratio in the patient group were significantly higher (P < 0.05) than those in the controls. After treatment, the lymphocyte count (P < 0.001); CD3⁺ (P < 0.01), CD4⁺ (P < 0.001), and CD19⁺ (P < 0.005) cells; and the CD4⁺/CD8⁺ ratio (P < 0.001) were decreased, but CD8⁺ cells were increased significantly (P < 0.001).

In summary, lack of testosterone action results in the enhancement of cellular and humoral immunity. The results of this study allowed us to conclude that testosterone deficiency affects both cell-mediated and humoral immunity, and these may be modulated with gonadotropin therapy in male patients with IHH.

This article has been cited by other articles:

				J J Corrales, M Almeida, R Burgo, M T Mories, J M Miralles, and A Orfao Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J. Endocrinol., June 1, 2006; 189(3): 595 - 604. [Abstract] [Full Text] [PDF]

				S. T. Page, S. R. Plymate, W. J. Bremner, A. M. Matsumoto, D. L. Hess, D. W. Lin, J. K. Amory, P. S. Nelson, and J. D. Wu Effect of medical castration on CD4+CD25+ T cells, CD8+ T cell IFN-{gamma} expression, and NK cells: a physiological role for testosterone and/or its metabolites Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E856 - E863. [Abstract] [Full Text] [PDF]

				C J Malkin, P J Pugh, P D Morris, K E Kerry, R D Jones, T H Jones, and K S Channer Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life Heart, August 1, 2004; 90(8): 871 - 876. [Abstract] [Full Text] [PDF]

				C. J. Malkin, P. J. Pugh, R. D. Jones, D. Kapoor, K. S. Channer, and T. H. Jones The Effect of Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles in Hypogonadal Men J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3313 - 3318. [Abstract] [Full Text] [PDF]

				P. J. Pugh, R. D. Jones, T.H. Jones, and K. S. Channer Heart failure as an inflammatory condition: potential role for androgens as immune modulators Eur J Heart Fail, December 1, 2002; 4(6): 673 - 680. [Abstract] [Full Text] [PDF]

				P.J. Pugh, K.M. English, T.H. Jones, and K.S. Channer Testosterone: a natural tonic for the failing heart? QJM, October 1, 2000; 93(10): 689 - 694. [Full Text] [PDF]